|
Call 1-866-549-8466 register login subscriptions - home individuals & families small businesses hsas doctors hospitals dentists drugs learn » start search drugs chlorpheniramine, carbetapentane, ephedrine, and phenylephrine search for a drug browse drugs a b c 0-9 chlorpheniramine, carbetapentane, ephedrine, and phenylephrine pronunciation: klor feh neer a meen.
104. Fifty-Second Annual Meeting of the Microscopy Society of America New Orleans, Louisiana Poster Presentations Authors: Wang, F., Head, J.F., and Elliott, R.L. "Characterization of Morphological and Cytotoxic Changes of Peripheral Blood Lymphocytes Induced by Interleukine-2" Authors: Elliott, R.L., Wang, F., Elliott, M.C., and Head, J.F. "An Immunocytochemical, Cytosol, and Ultrastructural Study of Tissue Ferritin in Breast Carcinoma" 105. Symposium on Stereotactic Core Needle Breast Biopsy Pompano Beach Medical Center Pompano Beach, Florida Paper Presented: "The Role of Stereotactic Core Needle Breast Biopsy in a Community Hospital" Elliott-Nowell-White Science Symposium Delta State University Cleveland, Mississippi Paper Presented: a. "Preparing for the Twenty-First Century" b. Awards Banquet Keynote Address "Who are the Real Heroes?" Sixteenth Annual International Conference of I.E.E.E., Engineering in Medicine and Biology Society Baltimore, Maryland Paper Presented: Authors: Elliott, R.L., Wang, F., Hailey, M.W., Head, J.F. "The Role Of Thermography In The Diagnosis and Treatment of Breast Cancer.
This study did not find a difference in rostral spread of spinal hyperbaric bupivacaine during Caesarean delivery when phenylephrine was used to maintain maternal arterial pressure, compared with ephedrine. The study was stopped after an interim analysis, at 54 patients, because of an unexpectedly high incidence of fetal acidosis in the ephedrine group. However, the lack of difference in block.
Diated women or that a significant number of permanent bladder complications have occurred. It is difficult to predict the response of a bladder tumor to irradiation strictly on the basis of histopathology. In general, the anaplastic infiltrating tumors are more radiosensitive. Any bladder infection which occurs during radiation therapy should be immediately and adequately treated to prevent the occurrence of sequelae. When infection is present bacterial studies of the urine should be made. If the patient has had previous fulgurations or bladder surgery, the radiation reactions are usually more prominent. Prior to the institution of radiation therapy the carcinoma should be staged. The staging is based upon cystoscopic examination, bimanual examination under anesthesia, biopsy, cystography and intravenous urography. Alkaline phosphatase, renal function, creatinine, complete blood cell count, and urinalysis are also done. Morrison and Deeley'2 in evaluating the transitional cell tumor response at one year according to dose given, stated that an increase in dose for example, from 5, ooo to 6, ooo rads tumor dose ; may not produce a greater disappearance rate of the primary lesion, and that there may be an optimum tumor dose; also, that different methods of fractionation should be investigated. DeWeerd and Colby4 carried out a planned program of combined radiation therapy and total or partial cystectomy and pelvic lymphadenectomy for bladder carcinoma. The majority of the lesions were Grade III Broders ; and Stages B, B2, and C Marshall-Jewett ; transitional cell carcinoma. The patients were divided into two groups. The Group I series included 27 patients. Cobalt 6o teletherapy or 6 mev. linear accelerator x-ray therapy was used. The treatment was directed to the bladder and adjacent pelvic lymph nodes. The total tumor dose was approximately 4, 800 rads given in 2 sessions, Both sessions were.
Phenylephrine 10 mg
BENZOIN latin. Styrax benzoin ; Benzoin has been used for 1000's of years in the East as a medicine and incense. In the West, we know the tincture by another name - 'Friars Balsam'. ACTIONS: USE: SAFETY: Anti-inflammatory Antiseptic Heals wounds.
Immediate openings for BE BC Emergency Medicine physicians. Level II E.D. 3000 visits per month. Salary benefits competitive. Ample Emergency Room training experience a must. General acute care 336 bed hospital located in university town minutes from Tulsa. Enjoy life with access to one of the largest man-made lake in the world. PA 713 ; The following group has submitted the notarized AAEM Certificate of Compliance, attesting to its compliance with AAEM's Policy Statements on Fairness in the Workplace and phenylpropanolamine.
1. Sullivan JM, Fowlkes LP. 1996 The clinical aspects of estrogen and the cardiovascular system. Obstet Gynecol. 87: 36S 43S. Oparil S. 1999 Hormones and vasoprotection. Hypertension. 33: 170 176. Walsh BW, Schiff I, Rosner B, Greenberg L, Ravnikar V, Sacks FM. 1991 Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins [see comments]. N Engl J Med. 325: 1196 1204. Sudhir K, Jennings GL, Funder JW, Komesaroff PA. 1996 Estrogen enhances basal nitric oxide release in the forearm vasculature in perimenopausal women. Hypertension. 28: 330 334. He XR, Wang W, Crofton JT, Share L. 1998 Effects of 17 -estradiol on sympathetic activity and pressor response to phenylephrine in ovariectomized rats. J Physiol. 275: R1202R1208. 6. Heesch CM, Rogers RC. 1995 Effects of pregnancy and progesterone metab.
NDC 68308-174-10 DESCRIPTION Each extended-release tablet contains: Guaifenesin . 1000 mg Phenylephrine HCl . mg D-Phen 1000 is formulated in a special base to provide a prolonged therapeutic effect. This product contains ingredients of the following therapeutic classes: expectorant and decongestant. D-Phen 1000 may also contain the following inactive ingredients: hypromellose, polyvinylpyrrolidone, silicon dioxide, magnesium stearate, hydroxypropyl cellulose, and purified water. Guaifenesin: 1, 2-propanediol, 3- ; -, is a white to slightly gray, crystalline powder, having a bitter taste. It may have a slight characteristic odor. It is soluble in water, alcohol, chloroform, glycerin, and propylene glycol. Phenylephrine hydrochloride: R ; -3-hydroxy--[ methylamino ; methyl] benzenemethanol hydrochloride is an adrenergic which occurs as white or practically white, odorless crystals, having a bitter taste. It is freely soluble in water and in alcohol. CLINICAL PHARMACOLOGY Guaifenesin is an expectorant which increases respiratory tract fluid secretions and helps loosen phlegm and bronchial secretions. By reducing the viscosity of secretions, guaifenesin increases the efficiency of the cough reflex and of ciliary action in removing accumulated secretions from the trachea and bronchi. Guaifenesin is readily absorbed from the gastrointestinal tract and is rapidly metabolized and excreted in the urine. Guaifenesin has a plasma half-life of one hour. The major urinary metabolite is - 2methoxyphenoxy ; lactic acid. Phenylephrine hydrochloride is a sympathomimetic amine which acts predominantly by a direct action on alpha ; -adrenergic receptors. In therapeutic doses, the drug has no significant stimulant effect on the beta ; - adrenergic receptors of the heart. Clinically, phenylephrine shrinks swollen mucous membranes, reduces tissue hyperemia, edema, and nasal congestion; and increases nasal airway patency. In therapeutic doses the drug causes little, if any, central nervous system CNS ; stimulation. INDICATIONS AND USAGE D-Phen 1000 is indicated for temporarily relieving symptoms of upper respiratory tract disorders such as sinusitis and hay fever; as well as for the temporary relief of coughs associated with respiratory tract infections and related conditions such as sinusitis, pharyngitis, bronchitis, and asthma, when these conditions are complicated by tenacious mucus and or mucus plugs and congestion. D-Phen 1000 is effective in a productive as well as a nonproductive cough, but is of particular value in a dry, nonproductive cough which tends to injure the mucous membrane of the air passages. CONTRAINDICATIONS D-Phen 1000 is contraindicated in patients with hypersensitivity to guaifenesin or with hypersensitivity or idiosyncrasy to sympathomimetic amines which may be manifested by insomnia, dizziness, weakness, tremor or arrhythmias. Patients known to be hypersensitive to other sympathomimetic amines may exhibit cross-sensitivity with phenylephrine. Phenylephrine is contraindicated in patients with hypertension or ventricular tachycardia and should be employed only with extreme caution in elderly patients or in patients with hyperthyroidism, bradycardia, partial heart block, myocardial disease, or severe arteriosclerosis. It is also contraindicated in patients on monoamine oxidase inhibitor MAOI ; therapy and for 14 days after stopping MAOI therapy see "Drug Interactions" section ; . WARNINGS Sympathomimetic amines should be used judiciously and sparingly in patients with hypertension, diabetes mellitus, ischemic heart disease, increased intraocular pressure, hyperthyroidism or prostatic hypertrophy. Sympathomimetics may produce central nervous system stimulation with convulsions or cardiovascular collapse with accompanying hypotension. Do not exceed recommended dosage. Hypertensive crises can occur with concurrent use of phenylephrine and MAO inhibitors and for 14 days after stopping MAOI therapy ; , indomethacin, or with betablockers and methyldopa. If a hypertensive crisis occurs, these drugs should be discontinued immediately and therapy to lower blood pressure should be instituted. Fever should be managed by means of external cooling. Before prescribing medication to suppress or modify a cough, it is important that the underlying cause of the cough is identified, that modification of the cough does not increase the risk of clinical or physiological complications, and that appropriate therapy for the primary disease is instituted. PRECAUTIONS General: Check with physician if cough persists after medication has been used for 7 days or if high fever, skin rash, or continued headache, or sore throat is present with cough. Information for Patients: Patient consultation should include the following information regarding proper use of this medication: Do not take more medication than the amount recommended. Take medication with food, water, or milk to minimize gastric irritation. Do not crush or chew tablets. Do not take monoamine oxidase inhibitors while taking this medication. If a dose is missed, the medication should be taken as soon as possible unless it is almost time for the next dose; no doubling doses. D-Phen 1000 should be stored in a tight, light-resistant container at temperatures between 15-30C 59-86F ; . Keep this and all medications out of the reach of children. In case of an accidental overdose, seek professional assistance or contact a poison control center immediately. Drug Interactions: Beta-adrenergic blockers and MAO inhibitors may potentiate the pressor effect of phenylephrine. Concurrent use of digitalis glycosides may increase the possibility of cardiac arrhythmias. Sympathomimetics may reduce the hypotensive effects of guanethidine, mecamylamine, methyldopa, reserpine and veratrum alkaloids. Concurrent use of tricyclic antidepressants may antagonize the effects of phenylephrine. Use of other vasopressor drugs during halothane anesthesia may cause serious cardiac arrhythmias. Drug Laboratory Test Interactions: Guaifenesin may increase renal clearance for urate and thereby lower serum uric acid levels. Guaifenesin may produce an increase in urinary 5hydroxyindoleacetic acid and may therefore interfere with the interpretation of this test for the diagnosis of carcinoid syndrome. It may also falsely elevate the VMA test for catechols. Administration of the drug should be discontinued 48 hours prior to the collection of urine specimens for such tests. Carcinogenesis, Mutagenesis, Impairment of Fertility: No data is available on the long-term potential for carcinogenesis, mutagenesis, or impairment of fertility in animals or humans. Pregnancy Category: Pregnancy Category C: Animal reproduction studies have not been conducted with Duraphen 1000. It is also not known whether D-Phen 1000 can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. D-Phen 1000 should be given to a pregnant woman only if clearly needed. Nursing Mothers: Small amounts of phenylephrine are excreted in breast milk. Use of D-Phen 1000 by nursing mothers is not recommended because of the higher than usual risk for infants from sympathomimetic amines. Pediatric Use: Very young children may be more sensitive to the effects, especially the vasopressor effects, of sympathomimetic amines like phenylephrine. Demonstrate safe use of a short-acting sympathomimetic amine before use of an extended-action formulation in pediatric patients. Appropriate studies on the relationship of age to the effects of guaifenesin have not been performed in the pediatric population. However, no pediatricspecific problems have been documented to date. Geriatric Use: Patients Approximately 60 Years And Older ; Geriatric patients are more likely to experience adverse reactions to sympathomimetics. Overdosage of sympathomimetics in this age group may cause hallucinations, convulsions, CNS depression, and death. Demonstrate safe use of a short-acting sympathomimetic amine before use of an extended-action formulation in geriatric patients and photofrin.
Phenylephrine effective dose
Clinicians sometimes ask for `easy understandable' properties instead of metrological exactness such as GFR in stead of creatinine and `Mean blood glucose' in stead of HbA1c ; . A challenge for EQA will be to expand EQA from being just a metrological assurance of the laboratory to the assessment of how laboratory test results are used and interpreted in the clinic. The development of the future EQA ought to be independent from that of manufacturers development of diagnostic tests. An important challenge will be to finance research and development of the necessary materials and methods. As EQA will be of minor interest for investors, funds must be raised from other sources. An effective networking among EQA organizers will be the only way to develop and improve independent EQA. EQA organizers should therefore share data and experiences for the purpose of comparison and learning. To improve such comparability a common terminology is needed for properties being investigated - regardless of speciality - and for procedures used by the participants to perform the investigations.
To record an administered vaccine, fill in the appropriate selection dot. Be sure to fill the dot in completely. For instance, if you administer a vaccine for Influenza, fill in the selection dot to the left of Inactivated or Live on the form. You are encouraged to enter the manufacturer and the lot number of the vaccine as well, though this information is not required. If you are a MCIR Vaccine Inventory Module VIM ; site you must fill in the Manufacturer and Lot Number information. To record the manufacturer, enter the two or three-character manufacturer abbreviation. Remember that entries should always be flush left. See Appendix B for a complete list of manufacturer abbreviations. If the vaccine you administered is not listed, use the Other Vaccine Code text box to record the entry, as described below and pilocarpine.
Geriatric Use: Confusion, hallucinations, seizures and CNS depression may be more likely to occur in geriatric patients taking sympathomimetic amines. Geriatric patients also may be more sensitive to the effects, especially the vasopressor effects, of sympathomimetic amines. Confusion, dizziness, sedation, hypotension, hyperexcitability, and anticholinergic side effects, such as dryness of mouth and urinary retention especially in males ; , may be more likely to occur in geriatric patients taking antihistamines. Geriatric patients may respond to usual doses of anticholinergics with excitement, agitation, drowsiness, or confusion. Geriatric patients are especially susceptible to the anticholinergic side effects, such as constipation, dryness of mouth, and urinary retention especially in males ; . If these side effects occur and continue or are severe, medication should probably be discontinued. Caution is also recommended when anticholinergics are given to geriatric patients, because of the danger of precipitating undiagnosed glaucoma. Memory may become severely impaired in geriatric patients, especially those who already have memory problems, with the continued use of anticholinergics, since these drugs block the action of acetylcholine, which is responsible for many functions of the brain, including memory function. ADVERSE REACTIONS The following adverse reactions have been observed with the use of phenylephrine, chlorpheniramine and methscopolamine: Arrhythmias, blood dyscrasia, CNS depression, CNS stimulation, dizziness, drowsiness, dryness of mouth, hallucinations, hypotension, hypertension, increased sensitivity of skin to sun, increased sweating, loss of appetite, paradoxical reaction, restlessness, skin rash, stomach upset or pain, thickening of mucus, tingling in hands or feet, trembling, troubled breathing, unusual tiredness or weakness, vomiting. Note: Agitation; confusion; difficult or painful urination; drowsiness; dizziness; and dryness of mouth, nose or throat are more likely to occur in the elderly. Nightmares, unusual excitement, nervousness, restlessness, or irritability are more likely to occur in children and the elderly. When anticholinergics are given to patients, especially children, where the environmental temperature is high, there is risk of a rapid increase in body temperature. DRUG ABUSE AND DEPENDENCE Central nervous system stimulants such as phenylephrine have been abused. At high doses, subjects commonly experience an elevation of mood, a sense of increased energy and alertness, and decreased appetite. Some individuals become anxious, irritable and loquacious. In addition to the marked euphoria, the user experiences a sense of markedly enhanced physical strength and mental capacity. With continued use, tolerance develops, the user increases the dose, and toxic signs and symptoms appear. Depression may follow rapid withdrawal. Stimulants, such as phenylephrine, are banned and tested for by the U.S. Olympic Committee USOC ; and the National Collegiate Athletic Association NCAA ; . OVERDOSAGE This product is comprised of pharmacologically different components sympathomimetic amine, antihistamine, anticholinergic ; . Therefore, it is difficult to predict the exact manifestation of symptoms in a given individual. Reaction to an overdose of this product may vary from CNS depression to stimulation. A description of symptoms which are likely to appear after ingestion of an excess of the individual components follows.
Phenylephrine iv dosing
Binding sites in rabbit brain: correlation with LH release. Soc Neurosci Abstr 11: 909 YoungLai EV, 1984. Changing patterns of peripheral hormones and sterols during maturation in the female rabbit. 7th Intl Congr Endocrinol, Quebec City: p. 1555. zivin JA, Waud DR, 1982. How to analyze binding, enzyme and uptake data: the simplest case, a single phase. Life Sci 30: 1407-22 and pima.
Figure 2. Effects of three-day NTG treatment of rabbits continuous or 12 h patch on patch off ; on concentration constriction curves generated in vitro with angiotensin II Ang II ; , phenylephrine Phe ; , serotonin 5-HT ; and potassium chloride KCl ; . Data are presented as the mean values SEM of 10 to experiments. See Figure 1 legend for explanation of symbols.
14 phenylephrine or calcium, inhibited in both cases, the increase in the intracellular calcium concentration. Testosterone and progesterone also inhibited the increase in the intracellular calcium concentration associated with either the administration of phenylephrine or the addition of calcium but higher concentrations of these hormones were needed 100 M in both cases and pindolol.
Mara Merritt, D.O. Family Health Centers Brewster, Washington Malini A. Nijagal, M.D. OB GYN Women's Health Services, County of Marin Alexa Oster, M.D. Resident Physician, Primary Care Internal Medicine University of California, San Francisco Roy Poses, M.D. Clinical Associate Professor of Medicine Brown University School of Medicine Erica Schockett, M.D. Resident Physician, Primary Care Internal Medicine University of Pennsylvania David Schriger, M.D. Professor, Department of Medicine Emergency Medicine University of California, Los Angeles Kendra Schwartz, M.D., MSPH Professor, Dept Family Medicine and Public Health Sciences Wayne State University, Detroit Ari Silver-Isenstadt, M.D. Franklin Square Pediatrics Baltimore, Maryland Ida Sim, M.D., Ph.D. Associate Professor of Medicine University of California, San Francisco Barbara Starfield, M.D. University Distinguished Professor Johns Hopkins University Norman Temple, Ph.D. Professor, Nutrition Athabasca University Eric J. Topol, M.D. Director, Scripps Translational Science Institute Scripps Research Institute Susan L. Troyan, M.D. Surgical Director, Beth Israel Deaconess Medical Center Harvard Medical School Adam Gilden Tsai, M.D., M . Philadelphia, PA.
And whether this COX isoform contributed to the enhanced response in the diabetic rat. We also addressed the release of 20-HETE, a potent renal vasoconstrictor eicosanoid, in response to AA, as earlier studies in the isolated perfused kidney indicated that the vasoconstrictor effect of 20-HETE was also dependent on COX activity and stimulation of PGH2 TxA2 receptors.15 Renal vasoconstrictor responses to AA were compared in control and diabetic rat kidneys in the presence of indomethacin to inhibit both COX isoforms and nimesulide to inhibit COX-2. As an index of COX activity, release of 6-ketoPGF1 was determined because the effects of AA were presumed to be dependent on endothelial conversion, and prostacyclin is the major endothelial prostanoid. Responses to phenylephrine were tested to ensure that nimesulide did not affect vasoconstrictor mechanisms. The results indicate that part of the renal vasoconstrictor effect of AA in the diabetic rat resulted from its conversion by COX-2, the renal expression of which was increased in the diabetic rat. It is unlikely that 20-HETE contributes to the response as release of 20-HETE was greatly reduced in the diabetic rat and unaffected by AA and pitocin.
Phenylephrine hydrochloride 1% nasal spray
Significantly increased in the BIO14.6 cardiomyopathic hamster heart compared with the normal control. In hypertrophic neonatal rat cardiomyocytes subjected to chronic phenylephrine treatment, we observed a marked depression of NCX activity measured as the rate of Na + i-dependent 45Ca2 + uptake or the rate of Nao + -dependent 45Ca2 + efflux. Depressed NCX activity was partially and independently reversed by acute inhibition of calcineurin and protein kinase C PKC ; activities with little effect on myocyte hypertrophic phenotypes. Studies of NCX1 deletion mutants expressed in CCL39 cells were consistent with the view that the 1 repeat is required for the action of endogenous calcineurin and that the large cytoplasmic loop may be required to maintain the interaction of the enzyme with its substrate. Our data suggest that NCX1 is a novel regulatory target for calcineurin and that depressed NCX activity might contribute to the etiology of in vivo cardiac hypertrophy and dysfunction occurring under conditions in which both calcineurin and PKC are chronically activated and phenylephrine.
Phenylephrine pregnancy safe
Mitral regurgitation with exercise, proctocream hc 2.5%, viscera 510, tumescent liposuction love handles and total parenteral nutrition software. Thymus gland mg, tunnel vision ryders, occipital cellulitis and quinacrine leg cramps or shin splint syndrome.
Phenylephrine maximum concentration
Phenyleph4ine, phenylephrin, phenylsphrine, ph3nylephrine, phwnylephrine, phenyoephrine, phenylephfine, phenlyephrine, pyenylephrine, pehnylephrine, phenyylephrine, phejylephrine, phenlephrine, phenylepyrine, pheenylephrine, phenylephrinw, phenylephine, phenylephrlne, phenylwphrine, phenylephrind.
Phenylephrine dosing
Phenylephrine 10 mg, phenylephrine effective dose, phenylephrine iv dosing, phenylephrine hydrochloride 1% nasal spray and phenylephrine pregnancy safe. Phenylephrine maximum concentration, phenylephrine dosing, acetaminophen 325 mg guaifenesin 200 mg phenylephrine hcl 5 mg and phenylephrine degradation pathway or phenylephrine stroke volume.
|
